# A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer

> **NCT01793636** · PHASE2 · TERMINATED · sponsor: **Queen Mary University of London** · enrollment: 49 (actual)

## Conditions studied

- Metastatic Clear Cell Renal Carcinoma

## Interventions

- **DRUG:** AZD2014
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01793636
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2014-05
- **Final completion:** 2015-11
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Inferior efficacy of study drug in renal indication.
- **Last updated:** 2014-06-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01793636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01793636, "A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01793636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*